AI & ML: A Review Of EMA And FDA's Approach
Source: Life Science Leader
By Sean Hilscher and Tanvi Mehta
Considering the feverish pace of innovation in the field of AI and the inevitable impact this family of technologies has on medical product development (specifically drug development), an overview of the approaches to AI/ML regulation by leading medical product regulatory authorities, the FDA and EMA, is timely. Below we outline the documents and guidances the two regulators have released thus far, comparing and contrasting their areas of focus and concern.
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more